Newsfeed

This area is a possible form of presentation for the integration of news sources relating to listed companies.
The presentation level is a template based on short news services, where users can get a quick overview of the latest news. The detailed views enable further research if interested.

This newsfeed is a compilation of current news from direct connections of TopTier NewsWire services related to listed companies. This feed is for demonstration purposes only. Sector-specific news, public relations and product information can be accessed via the GICS portals > Sector Intelligence section.

US6294441000
Reset filter
Do you already know our new terminal view? Click here.
FIGI: -
NRXP
NRx Pharmaceuticals, Inc.
GICS: Health Care · SECTOR: Healthcare · SUB-SECTOR: Biotechnology · THEMEFOLIO: $HLTH
NAME
NRx Pharmaceuticals, Inc.
ISIN
US6294441000
TICKER
NRXP
MIC
XNAS
REUTERS
NRXP.OQ
BLOOMBERG
NRXP US
Wed, 26.01.2022       NRx Pharmaceuticals
US6294441000

Los Angeles, California--(Newsfile Corp. - January 26, 2022) -  The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against NRx Pharmaceuticals, Inc. ("NRx" or "the Company") (NASDAQ: NRXP) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 1...
Read more
NRx Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Wed, 26.01.2022       NRx Pharmaceuticals
US6294441000

New York, New York--(Newsfile Corp. - January 26, 2022) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against NRx Pharmaceuticals, Inc. ("NRx" or the "Company") (NASDAQ: NRXP) (NASDAQ: NRXPW) on behalf of purchasers of NRx securities between June 1, 2021 and November 4, 2021, both dates inclu...
Read more
NRx Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Tue, 25.01.2022       NRx Pharmaceuticals
US6294441000

New York, New York--(Newsfile Corp. - January 25, 2022) - Pomerantz LLP announces that a class action lawsuit has been filed against NRx Pharmaceuticals, Inc. ("NRx" or the "Company") (NASDAQ: NRXP) (NASDAQ: NRXPW) and certain of its officers. The class action, filed in the United States District Court for the District of Delaware, and docketed...
Read more
NRx Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Tue, 25.01.2022       NRx Pharmaceuticals
US6294441000

Los Angeles, California--(Newsfile Corp. - January 25, 2022) -  The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against NRx Pharmaceuticals, Inc. ("NRx" or "the Company") (NASDAQ: NRXP) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 1...
Read more
NRx Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Mon, 24.01.2022       NRx Pharmaceuticals
US6294441000

Los Angeles, California--(Newsfile Corp. - January 24, 2022) -  The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against NRx Pharmaceuticals, Inc. ("NRx" or "the Company") (NASDAQ: NRXP) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 1...
Read more
NRx Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Fri, 21.01.2022       NRx Pharmaceuticals
US6294441000

Los Angeles, California--(Newsfile Corp. - January 21, 2022) -  The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against NRx Pharmaceuticals, Inc. ("NRx" or "the Company") (NASDAQ: NRXP) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 1...
Read more
NRx Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Fri, 21.01.2022       NRx Pharmaceuticals
US6294441000

San Diego, California--(Newsfile Corp. - January 20, 2022) - The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers of NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) (NASDAQ: NRXPW) securities between June 1, 2021 and November 4, 2021, inclusive (the "Class Period") have until March 21, 2022 to seek appointment as lead plaintiff i...
Read more
NRx Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Thu, 20.01.2022       NRx Pharmaceuticals
US6294441000

Los Angeles, California--(Newsfile Corp. - January 20, 2022) -  The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against NRx Pharmaceuticals, Inc. ("NRx" or "the Company") (NASDAQ: NRXP) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 1...
Read more
NRx Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Thu, 20.01.2022       NRx Pharmaceuticals
US6294441000

New York, New York--(Newsfile Corp. - January 19, 2022) - Pomerantz LLP announces that a class action lawsuit has been filed against NRx Pharmaceuticals, Inc. ("NRx" or the "Company") (NASDAQ: NRXP; NRXPW) and certain of its officers. The class action, filed in the United States District Court for the District of Delaware, and docketed under 22-c...
Read more
NRx Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Wed, 19.01.2022       NRx Pharmaceuticals
US6294441000

New York, New York--(Newsfile Corp. - January 19, 2022) - Gainey McKenna & Egleston announces that a class action lawsuit has been filed against NRx Pharmaceuticals, Inc. ("NRx") (NASDAQ: NRXP) (NASDAQ: NRXPW) in the United States District Court for the District of Delaware on behalf of investors who purchased NRx's common stock between June 1,...
Read more
NRx Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Mon, 08.11.2021       NRx Pharmaceuticals
US6294441000

New York, New York--(Newsfile Corp. - November 8, 2021) - Pomerantz LLP is investigating claims on behalf of investors of NRx Pharmaceuticals, Inc. ("NRx" or the "Company") (NASDAQ: NRXP). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether NRx and certa...
Read more
NRx Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink